Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 173.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (44.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.5% (LTM)
  • Share price is 242.6% higher than minimum and 4.1% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (39.7x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $78 353.4 mln (-0.293% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-2.1%)1064.29
year average price 847.01  


year start price 785.41 2025-01-26

min close price 625.65 2025-08-08

max close price 1109.94 2025-11-25

current price 1064.29 2026-01-25
Common stocks: 900 605 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.5%
EV / LTM EBITDA: 39.7x
EV / EBITDA annualized: 31.6x
Last revenue growth (y/y):  +53.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +28.1%
Historical growth of EBITDA:  +59.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 958 505
Net Debt ($m): 32 651
EV (Enterprise Value): 991 156
EBITDA LTM ($m): 24 974
EV / LTM EBITDA: 39.7x
Price to Book: 40.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-24defenseworld.net

BAM Wealth Management LLC Invests $1.09 Million in Eli Lilly and Company $LLY

2026-01-23investors.com

Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues

2026-01-23cnbc.com

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

2026-01-21zacks.com

FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate

2026-01-21seekingalpha.com

Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot

2026-01-17youtube.com

Eli Lilly, Nvidia team up in a $1B AI innovation lab.

2026-01-17fool.com

Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026?

2026-01-16fool.com

This Company Is Doubling Down on AI. Is the Stock a Buy?

2026-01-16zacks.com

LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling

2026-01-16forbes.com

Buy The Dip In LLY Stock?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data